| Literature DB >> 31667415 |
Sugandha Singhal1, Pankaj Khanna2, Leena Khanna1.
Abstract
Novel Schiff bases (SBs) were synthesized by condensation of 2-(1-Amino benzyl) benzimidazole with heterocyclic and aromatic carbonyl compounds. The structural characterization was done using 1H, 13C NMR, FTIR and ES-MS spectroscopic techniques. The in silico pharmacokinetics showed that nearly all compounds obeyed Lipinski rule of 5 with low toxicity and metabolic stability. The global reactivity descriptors were calculated using DFT approach. The molecular docking result of SBs with ct-DNA suggested interaction via groove binding mode. The antibacterial activity was tested against S. aureus and E. coli, indicated significant inhibition than reference drug. The compound 4d gave best results at 50 μg ml-1 concentrations. UV/Vis and Fluorescence spectroscopy tools were used to evaluate ct-DNA binding ability of compounds 4a-e through hypochromic shift. The steady state fluorescence predicted a moderate binding constant of 1.12 × 104 for 4d, indicative of non-intercalative mode.Entities:
Keywords: Antibacterial activity; Molecular docking; Organic chemistry; Pharmaceutical chemistry; Pharmacokinetics; Schiff base ligands (SBs)
Year: 2019 PMID: 31667415 PMCID: PMC6812229 DOI: 10.1016/j.heliyon.2019.e02596
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Scheme 1Synthetic protocol for 2-(1-Amino benzyl) benzimidazole Schiff base derivatives 4a–4h.
Spectral Data of synthesized compound 3a and SBs 4a–h.
| Comp. | M.P. (°C) | IR (cm−1) | EIMS, m/z | 1H NMR 400MHz (δ, CDCl3) | 13C NMR 75.5 MHz (δ, CDCl3) | Elemental Analysis |
|---|---|---|---|---|---|---|
| 280 | 3352 (NH2), 3305 (N–H), 3052 (Ar C–H), 2889, 2661 (CH3C–H), 1155 (C–N), 1592 (Ar C=C) | 224 (M + H)+ | 2.03 (2H,d,NH2), 2.45 (1H,s,NH), 4.32 (1H,s,CH), 7.26–7.37 (9H,m,Ar–H) | 55.8, | Calcd.: C, 75.31; H, 5.87; N, 18.82; found: C, 75.34; H, 5.85; N, 18.81 | |
| 312 | 3305 (N–H), 3052 (Ar C–H), 2889, 2661 (-CH), 1652 (C=N), 1155 (C–N), 1577 (Ar C=C) | 352.38 (M+) | 8.18 (2H,s,NH), 4.25 (1H,s,CH), 6.65–6.77(4H,m,Ar–H), 6.83–6.85 (9H,m,Ar–H) | 55.8, | Calcd.: C, 74.98; H, 4.58; N, 15.90; found: C, 74.95; H, 4.59; N, 15.92 | |
| 315 | 3740 (N–H), 2882, 2665 (C–H), 1742 (C=O), 1575 (Ar C=C), 1149 (C–N), 1652 (C=N), 1155 (C–N), 727 (C–Cl) | 386.83 (M+) | 8.18 (2H,s,NH), 4.25 (1H,s,CH), 6.65–6.77(4H,m,Ar–H), 6.83–6.85 (9H,m,Ar–H) | 55.8, | Calcd.: C, 68.31; H, 3.9; N, 14.48; Cl, 9.16; found: C, 68.33; H, 3.9; N, 14.46; Cl, 9.15 | |
| 318 | 3702 (N–H), 2882, 2655 (C–H), 1745 (C=O), 1577 (Ar C=C), 1652 (C=N), 1148 (C–N), 682 (C–Br) | 431.28 (M+) | 8.18 (2H,s,NH), 4.27 (1H,s,CH), 6.78–6.85 (3H,q,Ar–H), 7.24–7.25 (9H,m,Ar–H) | 55.8, | Calcd.: C, 61.27; H, 3.51; N, 12.99; Br, 18.53; found: C, 61.28; H, 3.52; N, 12.97; Br, 18.55 | |
| 312 | 3740 (N–H), 2882, 2665 (C–H), 1742 (C=O), 1577 (Ar C=C), 1652 (C=N), 1149 (C–N) | 370.28 (M+) | 8.18 (2H,s,NH), 4.25 (1H,s,CH), 6.65–6.77 (4H,m,Ar–H), 6.83–6.85 (9H,m,Ar–H) | 55.8, | Calcd.: C, 71.34; H, 4.08; N, 15.13; F, 5.13; found: C, 71.35; H, 4.06; N, 15.15; F, 5.12 | |
| 296 | 3305 (N–H), 2881, 2655 (C–H), 1700 (C–O), 1577 (Ar C=C), 1652 (C=N), 1148 (C–N) | 301.34 (M+) | 4.11 (1H,s,CH), 4.28 (1H,s,CH), 6.65 (2H,dd, Ar–H), 6.75–6.78 (4H,q,Ar–H), 6.81–6.84 (5H,m,Ar–H), 7.26 (1H,t,Ar–H), 8.18 (1H,s,NH) | 55.8, | Calcd.: C, 75.37; H, 5.02; N, 13.94; found: C, 75.38; H, 5.05; N, 13.90 | |
| 290 | 3462 (N–H), 2882, 2655 (C–H), 1577 (Ar C=C), 1652 (C=N), C–N (1149) | 311.37 (M+) | 4.11 (1H,s,CH), 4.28 (1H,s,CH), 6.77–6.84 (4H,m,Ar–H), 7.24–7.26 (10H,m,Ar–H), 8.18 (1H,s,NH) | 55.8, | Calcd.: C, 81.00; H, 5.50; N, 13.49; found: 81.03; H, 5.48; N, 13.48 | |
| 294 | 3305 (N–H), 2881, 2655 (C–H), 1576 (Ar C=C), 1652 (C=N), 1148 (C–N) | 361.43 (M+) | 4.11 (1H,s,CH), 4.28 (1H,s,CH), 6.76–6.84 (7H,m,Ar–H), 7.25–7.26 (9H,m,Ar–H), 8.18 (1H,s,NH) | 55.8, | Calcd.: C, 83.08; H, 5.30; N, 11.63; found: C, 83.09; H, 5.33; N, 11.59 | |
| 298 | 3305 (N–H), 2881, 2655 (C–H), 1577 (Ar C=C), 1652 (C=N), 1148 (C–N) | 341.40 (M+); | 4.05 (3H,s,OCH3), 4.05 (1H,s,CH), 4.279 (1H,s,CH), 6.77–6.84 (4H,q,Ar–H), 7.2–7.26 (9H,m,Ar–H), 8.18 (1H,s,NH) | 55.8, | Calcd.: C, 77.40; H, 5.61; N, 12.31; found: C, 77.38; H, 5.63; N, 12.30 |
Drug likeliness properties of synthesized SBs 4a–4h.
| Property | Compounds | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Log P | 2.5 | 4.32 | 4.97 | 5.0 | 3.48 | 3.80 | 4.55 | 5.71 | 4.58 |
| TPSA | 54.71 | 73.91 | 73.91 | 73.91 | 73.91 | 54.19 | 41.05 | 41.05 | 50.28 |
| Natoms | 17 | 27 | 28 | 28 | 28 | 23 | 24 | 28 | 26 |
| MW | 223.28 | 352.4 | 386.84 | 431.29 | 370.39 | 301.35 | 311.39 | 361.45 | 341.41 |
| nOH | 3 | 5 | 5 | 5 | 5 | 4 | 3 | 3 | 4 |
| nOHNH | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| Nviolations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Nrotb | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 |
| Volume | 208.39 | 312.31 | 325.85 | 330.20 | 317.25 | 273.34 | 291.77 | 335.76 | 317.32 |
ADME Properties of synthesized SBs 4a–h.
| Property | Compounds | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| BBB | 2.19 | 2.32 | 2.87 | 3.03 | 2.10 | 4.78 | 9.01 | 11.18 | 6.83 |
| Caco 2 | 19.23 | 24.84 | 29.76 | 29.46 | 34.77 | 24.29 | 27.51 | 27.93 | 56.64 |
| HIA | 90.53 | 92.68 | 93.42 | 93.80 | 92.70 | 93.70 | 94.16 | 94.75 | 92.72 |
| MDCK | 354.59 | 221.71 | 112.82 | 4.30 | 181.03 | 59.88 | 100.48 | 77.09 | 112.82 |
| PPB* | 46.34 | 87 | 89 | 88 | 89 | 90 | 92 | 89 | 87 |
| SP* | -3.87 | -3.99 | -4.09 | -3.94 | -4.33 | -2.48 | -2.42 | -2.14 | -3.12 |
*BBB: Blood Brain Barrier. *HIA: Human Intestinal Absorption. *PPB: Plasma Protein Binding. *SP: Skin Permeability.
Electronic energy calculation values of synthesized SBs 4a–h.
| Compound | EHOMO | ELUMO | Energy gap | χ | ||
|---|---|---|---|---|---|---|
| -0.3334 | -0.1744 | 0.1590 | -0.2539 | 0.0795 | 0.2539 | |
| -0.0641 | -0.0075 | 0.0566 | -0.0358 | 0.0283 | 0.0358 | |
| -0.0713 | -0.0152 | 0.0561 | -0.0432 | 0.0280 | 0.0432 | |
| -0.0675 | -0.0113 | 0.0562 | -0.0394 | 0.0281 | 0.0394 | |
| -0.0639 | -0.0077 | 0.0562 | -0.0358 | 0.0281 | 0.0358 | |
| -0.1654 | -0.0373 | 0.1281 | -0.1013 | 0.0640 | 0.1013 | |
| -0.3187 | -0.1959 | 0.1228 | -0.2573 | 0.0614 | 0.2573 | |
| -0.3186 | -0.1964 | 0.1222 | -0.2575 | 0.0611 | 0.2575 | |
| -0.2221 | -0.0458 | 0.1763 | -0.1339 | 0.0881 | 0.1339 |
*μ is the chemical potential which indicates spontaneous decomposition. *ƞ is the hardness. *χ is the electronegativity.
Fig. 1HOMO-LUMO plots for 2-(1-amino benzyl) benzimidazole, 3a and synthesized SB 4d.
Docking parameters via Autodock4.2
| Compounds | Property | ||
|---|---|---|---|
| Free Energy of Binding Kcal/mol | Inhibition constant at 298.15 K (μM) | RMSD from reference structure | |
| -8.17 | 1.90 | 70.17 | |
| -7.71 | 2.24 | 73.04 | |
| -8.24 | 4.01 | 74.55 | |
| -8.47 | 0.512 | 75.33 | |
| -7.36 | 0.617 | 78.90 | |
| -2.37 | 24.98 | 78.22 | |
| -2.32 | 28.09 | 79.21 | |
| -3.41 | 15.41 | 70.06 | |
Fig. 2Docked poses 1–3 of compound 4d within minor grove of ct-DNA (PDB ID: 1BNA).
Fig. 3Docked poses 4 and 5 of compound 4d within minor grove of ct-DNA (PDB ID: 1BNA).
Fig. 4Docking of compounds 4a–e with ct-DNA (PDB ID: 1BNA).
Fig. 5Docking of compounds 4f–h with ct-DNA (PDB ID: 1BNA).
Fig. 6Antibacterial activity of SBs (4a–h) against Gram positive and Gram negative bacteria (50 and 100 μg/ml concentration).
Antimicrobial activity [zone of inhibition (mm)] of synthesized SBs (4a–h) against E.coli and S.aureus.
| Compound | Control | Reference | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| E.coli 50ug/ml (inhibiton/mm) | 0 | 14 | 20 | 22 | 25 | 20 | 14 | 27 | 25 | 14 |
| E.coli | 0 | 20 | 20 | 22 | 25 | 22 | 15 | 30 | 28 | 14 |
| S.aureus 50ug/ml (inhibiton/mm) | 0 | 9 | 14 | 16 | 20 | 15 | 14 | 16 | 13 | 17 |
| S.aureus | 0 | 10 | 14 | 18 | 22 | 16 | 15 | 16 | 13 | 17 |
Fig. 7UV-Vis interaction of SBs 4a–4e (100 μM) with increasing concentration of ct-DNA.
Fig. 8Fluorescence of 4d (a) titration quenching spectrum (b) Stern-Volmer quenching plot.
Fig. 9The plot of log (Fo/F) vs log [Q] to determine value of association constant and number of binding sites of ct-DNA with SB 4d.
DNA binding constant (K), Stern-Volmer constant (Kq) and number of binding sites (n) for SBs 4a–4e using plot of log [(Fo-F)/F] vs. log [Q].
| Compound | K (M−1) | Kq (M−1) | N |
|---|---|---|---|
| 0.80 × 104 | 7.98 × 1012 | 1.09 | |
| 1.05 × 104 | 8.43 × 1012 | 1.03 | |
| 0.98 × 104 | 8.12 × 1012 | 1.06 | |
| 1.12 × 104 | 8.78 × 1012 | 1.02 | |
| 0.91 × 104 | 8.03 × 1012 | 1.05 | |
| Thiabendazole | 6.32 × 103 | 4.13 × 1011 | 1.05 |
| Olanzapine | 2.28 × 103 | 2.13 × 1011 | 1.01 |
| Pregabain | 2.24 × 103 | 1.59 × 1011 | 1.04 |